Urologic Research at the University of Chicago


The Section of Urology at the University of Chicago has a strong legacy and rich tradition of clinical research in urologic oncology. Our objectives are to improve the treatment of patients with cancer. Our focus is on the patients and how we, as scientists, can improve their lives.


New Cancer Therapy Program
The Program in New Cancer Therapies was created to consolidate clinical and laboratory research efforts in improving the management of patients with urologic cancers. The primary objective is to develop, advance, and subsequently offer state-of-the-art treatments to patients with urologic cancers by developing improved therapies and treatment paradigms that incorporate novel anti-cancer agents and technologies as a compliment to conventional surgical therapy.


Our endeavors are based on the following three principles:

  • Combining conventional surgical therapies with both standard and experimental adjuvant treatments.
  • Embracing minimally-invasive technologies and expanding their role in patient care.
  • Advocating investigator-initiated clinical trials designed in the true spirit of translational research, in which laboratory discoveries are applied to patient management and observations from the clinic are explored at the bench. Correlative scientific investigation will aid in improved understanding of molecular, genetic, and biochemical pathophysiologic processes of these cancers and in the creation of better management strategies.

Clinical Trials
New drugs and treatments are often evaluated through a series of studies called clinical trials. These are closely monitored and regulated studies in which the effectiveness and safety of new drugs and technologies are evaluated.
Clinical trials consist of three phases. The purpose of phase 1 is to determine possible side effects of a drug or treatment method. If results from phase 1 trials are positive, the drug is tested in a larger group of patients to determine how it affects a specific disease and what its short-term side effects may be. Phase 2 studies focus on comparing the new treatment with the current treatment or placebo. In phase 3 clinical trials, the drug is further studied for safety and efficacy in a much larger group of patients who have the disease being studied.


If you want to learn more about the trials underway or planned or to make an appointment, we invite you to call the Section of Urology at (773)702-0792.